Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: Results of a phase study

British Journal of Urology

Volumn 79, Issue 3, 1997, Pages 432-438

  Cookson, M S ^a   Sogani, P C ^a   Russo, P ^a   Sheinfeld, J ^a   Herr, H ^a   Dalbagni, G ^a   Reuter, V E ^a   Begg, C B ^a   Fair, W R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Androgen deprivation therapy,; Biochemical recurrence; Prostate cancer; Prostatectomy

Indexed keywords

ANTINEOPLASTIC AGENT; FLUTAMIDE; GOSERELIN;

ARTICLE; BIOCHEMISTRY; CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FLUTAMIDE; GOSERELIN; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0031401071     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Parker SI. Tong T, Bolden S. Wingo PA. Cancer statistics. 1995. ÇA Cancer }Clin 1996: 46: 5-27
2. Catalona WJ. Richie JP. Ahmann FR et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 1994: 151: 1283-90
3. Potosky AL, Miller BA, Albertsen PC. Kramer BS. The role of increasing defection in the rising incidence of prostate cancer. ]AMA 1995; 273: 548-52
4. Zincke H.Oesterling JE, Blute ML. Bergstralh E], Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. / Ural 1994; 152: 1850-7
5. Murphy GP. Mettlin C. Menk H. Winchester DP. Davidson AM. National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons commission on cancer. / Urol 1994: 152: 1817-9
6. Walsh PC, Partin AW. Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. / Urol 1994; 152: 1831-6
7. Catalona WJ. Smith DS. 5-year tumour recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. / Urol 1994; 152: 1837-42
8. Bostwick DG. Myers RP. Oesterling (E. Staging of prostate cancer. Sem Sure; Oncol 1994; 10: 60-72
9. Paulson DP. Impact of radical prostatectomy in the management of clinically localized disease. / Urol 1994: 152: 1826-30
10. Monfette G. Dupont A. Labrie F. Temporary combination therapy with Flutamide and Trypex as adjuvant to radical prostatectomy for the treatment of early stage prostate cancer. In Labrie F ed., Early Stage Prostate Cancer: Diagnosis and Choice of Therapy. New York: Elsevier Science Publishers BV, 1989; 41-5]
11. Soloway M. TreEitment of early prostate cancer. Harm Res 1989: 32 (suppl): 59-61
12. Crawford ED. Changing concepts in the management of advanced prostale cancer. Urology 1995: 44: 67-74
13. Labrie F, Belanger A. Dupont A. Luu-The V, Simard ]. Labrie C. Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med 1993: 16: 475-92
14. Huggins C, Hodges CV. Studies on prostate cancer; effect of castration, estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7
15. Vallett BS. Radical perineal prostatectomy subsequent to bilateral orchiectomy. Del Med J 1944; 16: 19-23
16. Parlow AL. Advanced cancer of the prostate: a consideration of the value of radical prostatectomy in selected cases. New York }Med 1945; 45: 383-7
17. Colston JA, Brendler H. Endocrine therapy in carcinoma of the prostate: preparation of patients for radical perineal prostatectomy. ]AMA 1947; 134: 848-53
18. Parlow AL, Scott WW. Hormone control therapy as a preparation for radical perineal prostatectomy in advanced carcinoma of the prostate. New York }Med 1949: 49: 629-34
19. Guttierrez R. New horizons in the surgical management of carcinoma of the prostate gland. Am ] Surg 1949; 78: 147-69
20. Scott WW. An evaluation of endocrine therapy plus radical perineal prostatectomy in the treatment of advanced carcinoma of the prostate. / Urol 1964; 91: 97-102
21. Chute R, Fox BM. Non-resectable carcinoma of the prostate rendered resectable by endocrine therapy. / Urol 1966; 95: 577-9
22. Scott WW, Boyd HL. Combined hormone control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate: a retrospective study based upon 25 years of experience. / Urol 1969; 101: 86-92
23. Aprikian AG, Fair WR, Reuter VE et al. Experience with neoadjuvant diethylstilbestrol and radical prostatectomy in patients with locally advanced prostate cancer. Br / Urol 1994; 74: 630-6
24. Kennedy TJ, Sonneland AM, Marlett MM, Troup RH. Luteinizing hormone-releasing hormone downstaging of clinical stage C prostate cancer. / Urol 1992; 147: 891-3
25. Van Poppel H, Ameye F, Oyen R. Van de Voorde W, Baert L. Radical prostatectomy for localized prostate cancer. Eur ] Surg Oncol 1992; 18: 456-62
26. Schulman CC. Sassine AM. Neoadjuvant hormonal treatment of locally advanced prostate cancer: does it make sense? Clin Invest Med 1993: 16: 523-31
27. MacFarlane MT, Abi-Aad A, Stein A. Danella J, Belldegrum A, deKernion J B. Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer. / Urol 1993; 150: 132-4
28. Andres EA, Danesghari F, Crawford ED. Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate. Clin Invest Med 1993; 16; 510-5
29. Van Poppel H, Ridder DD, Elgamal A et al. Néo-adjuvant hormonal therapy before radical prostatectomy reduces the number of positive surgical margins in T2 prostate cancer: interim results of a prospective randomized trial. J Urol 1995; 154: 429-34
30. van den Ouden D, Davidson PT, Hop W, Schröder FH. Radical prostatectomy as monotherapy for locally advanced (stage T3) prostate cancer. J Urol 1993; 151: 646-51
31. Morgan WR, Bergstralh EJ, Zincke H. Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology 1993; 41: 113-20
32. Boxer RJ, Kaufman JJ, Goodwin WE. Radical prostatectomy for carcinoma of the prostate: 1951-1976. A review of 329 patients. / Urol 1977; 117: 208-13
33. 3 Labrie F, Cusan L. Gomez J-L et al. Down-staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a lutenizing hormone-releasing hormone. Urology 1994; 44 (6A): 29-37
34. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Baez-Puras A for the Lupron Depot Neoadjuvant Prostate Cancer Study Group. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2BNxMO) prostate cancer. / Urol 1995; 154: 424-8
35. El-Galley R, Northway R, Petros JA et al. PSA recurrence after radical prostatectomy. / Urol 1996: 155: 420A
36. Cleave ME, Goldenberg L, Jones EC, Bruchovsky N, Sullivan LD. Biochemical and pathological effects of 8 months of neoadjuvant withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. JUrol 1996; 155: 213-9